Trials / Completed
CompletedNCT02684279
Dasotraline Binge Eating Disorder Extension Study
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 533 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 56 Years
- Healthy volunteers
- Not accepted
Summary
Binge Eating Disorder Extension Study.
Detailed description
This is a Phase 3, 12 month, multicenter, open-label, flexibly-dosed, safety study in adults with Binge Eating Disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasotraline | Dasotraline 4, 6, 8 mg flexibly dosed once daily |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2019-06-24
- Completion
- 2019-06-24
- First posted
- 2016-02-17
- Last updated
- 2020-08-12
- Results posted
- 2020-08-12
Locations
57 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02684279. Inclusion in this directory is not an endorsement.